![\"\"](\"https:\/\/wp-ilts-media.s3.amazonaws.com\/wp-content\/uploads\/2018\/09\/17124820\/02-ILTS_Logo_Rotterdam_Care-Banner-1024x195.jpg\"){kind=logo}
<\/p>\n<\/p>\n
Consensus Conference by ILTS: Transplant oncology is a new concept encompassing multiple disciplines of transplantation medicine and oncology to take hepatobiliary cancer treatment and research to the next level. The Consensus Conference in Rotterdam convened worldwide experts and opinion leaders in transplant surgery, radiology and oncology, hepatology and immunology to discuss the frontiers and future perspectives of multidisciplinary management of hepatobiliary malignancies.<\/p>\n The main topics included liver transplantation for hepatocellular carcinoma, cholangiocarcinoma, colorectal and neuroendocrine liver metastases, pediatric malignancy, therapies for cancer recurrence after liver transplantation and the role of novel chemotherapeutic and biological agents to enhance transplantation outcomes.<\/p>\n After a morning of inspiring lectures, delegates joined afternoon working groups with the task of finding solutions and suggesting guidelines for topic-related issues.<\/p>\n The Program<\/strong><\/p>\n Introductory Lectures (8:00 \u2013 9:30): <\/strong><\/p>\n Consensus Conference Lectures (9:30 \u2013 13:00)<\/strong><\/p>\n Working group discussion (14:00 \u2013 15:30)<\/strong><\/p>\n Working group presentations with statements (16:00 -18:00) Summary (18:00-18:30) Download the detailed Program<\/strong> here<\/strong><\/a>.<\/p>\n CONTINUING MEDICAL EDUCATION (CME) CREDITS<\/strong><\/p>\n The ILTS 2019 Consensus Conference: Transplant Oncology – The Future of MultidisciplinaryManagement, Rotterdam, Netherlands, 07\/02\/2019-07\/02\/2019 has been accredited by theEuropean Accreditation Council for Continuing Medical Education (EACCME\u00ae) with 7 European CMEcredits (ECMEC\u00aes). Each medical specialist should claim only those hours of credit that he\/sheactually spent in the educational activity.<\/p>\n Through an agreement between the Union Europ\u00e9enne des M\u00e9decins Sp\u00e9cialistes and the AmericanMedical Association, physicians may convert EACCME\u00ae credits to an equivalent number of AMA PRACategory 1 CreditsTM. Information on the process to convert EACCME\u00ae credit to AMA credit can befound at www.ama-assn.org\/education\/earn-credit-participation-international-activities.<\/p>\n Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME\u00ae forECMEC\u00aes are deemed to be Accredited Group Learning Activities (Section 1) as defined by theMaintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.<\/p>\n Ethical MedTech Assessments<\/strong><\/p>\n ILTS 2019 Consensus Conference: Transplant Oncology \u2013 the Future of Multidisciplinary Management is now compliant with the MedTech Europe Code of Ethical Business Practice www.ethicalmedtech.eu<\/a>.<\/p>\n After rigorous selection, K.I.T. Group GmbH is among the first organisations to earn the Medtech Ethical Charter. This is the official certification of those PCOs that demonstrate understanding and commitment to the new regulations. (https:\/\/www.ethicalmedtech.eu\/ethical-charter\/chartered-organisations\/<\/a>).<\/p>\n Working with K.I.T. Group GmbH, an officially licensed Medtech Trusted Partner, will offer very real advantages to Medtech member companies, medical societies, conference venues and hotels. Read more here<\/a>.<\/p>\n AIFA – The official agency for Italian delegates and industry: <\/strong><\/p>\n Barbara Mantegazza Aria di Viaggi Srl \u2013 Congress and Fair Department![\"\"](\"https:\/\/wp-ilts-media.s3.amazonaws.com\/wp-content\/uploads\/2019\/01\/22115313\/see-full-program-here_button-300x129.png\")
<\/a>![\"\"](\"https:\/\/wp-ilts-media.s3.amazonaws.com\/wp-content\/uploads\/2019\/01\/22115531\/meet-the-speakers-and-working-group-leaders_button-300x129.png\")
<\/a><\/div><\/p><\/div><\/p>\n<\/div><\/p><\/div>\n
\n<\/strong>Thursday, February 7, 2019
\nHilton Rotterdam<\/p>\n<\/div><\/p><\/div>\n<\/div><\/p><\/div>\n<\/div><\/p><\/div>\n<\/div><\/p><\/div>\n
\n\n
\nJohn Roberts, MD University of California San Francisco \u2013 San Francisco, CA, USA<\/em><\/li>\n
\nVincenzo Mazzaferro, MD, Fondazione IRCCS Instituto Nazionale dei Tumori di Milano \u2013 Milan, Italy<\/em>
\nBruno Sangro, MD, PhD The University of Navarra School of Medicine \u2013 Pamplona, Spain<\/em><\/li>\n
\nR. Mark Ghobrial MD, PhD, FRCS Methodist Hospital \u2013 Houston, TX, USA<\/em>
\nMilind Javle, MD University of Texas MD Anderson Cancer Center \u2013 Houston, TX, USA<\/em><\/li>\n<\/ul>\n\n
\nWestern experience:
\nFrancis Yao, MD University of California: San Francisco \u2013 San Francisco, CA, USA<\/em>
\nEastern experience:
\nAvi Soin, MD Medanta \u2013 The Medicity, India<\/em><\/li>\n
\nJulie Heimbach, MD Mayo Clinic Rochester \u2013 Rochester, ME, USA<\/em>
\nGonzalo Sapisochin, MD Toronto General Hospital \u2013 Toronto, Canada<\/em><\/li>\n
\nJames Eason, MD Methodist University Transplant \u2013 Memphis, TN, USA<\/em>
\nPal Dag Line, MD, PhD Oslo University Hospital \u2013 Oslo, Norway<\/em><\/li>\n
\nMohamed Rela, MD, Dr.Rela Institute & Medical Centre \u2013 Chennai, India<\/em>
\nTaizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences \u2013 Kumamoto, Japan<\/em><\/li>\n
\nSherrie Bhoori, MD National Cancer Institute \u2013 Milan, Italy<\/em>
\nShusen Zheng, MD, PhD Zhejiang University \u2013 Hangzhou, China<\/em><\/li>\n
\nDAA therapies
\nMarina Berenguer, MD Hospital La Fe \u2013 Valencia, Spain<\/em>
\nNASH\/HCC
\nPatrizia Burra, MD, PhD Padova University Hospital \u2013 Padova, Italy<\/em><\/li>\n<\/ul>\n<\/div><\/p><\/div>\n\n
\n– Updates on the selection criteria
\n– Prediction models
\n– Downstaging and bridging therapies
\n– Should small tumors be treated by ablation and reserve OLT for large cancers?
\nGroup leaders: Vincenzo Mazzaferro, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano \u2013 Milan, Italy<\/em>
\nNeil Mehta, PhD University of California: San Francisco \u2013 San Francisco, CA, USA<\/em><\/em>
\nAvi Soin, MD Medanta \u2013 The Medicity, India
\n<\/em><\/em><\/div><\/p><\/div><\/li>\n
\n– Hilar CCA
\n– Intrahepatic CCA
\n– Mixed HCC\/CCA (Outcomes, diagnostic and prognostic tools, adjuvant treatments)
\nGroup Leaders: Julie Heimbach, MD Mayo Clinic Rochester \u2013 Rochester, ME, USA<\/em>
\nGonzalo Sapisochin, MD Toronto General Hospital \u2013 Toronto, Canada<\/em>
\nMilind Javle, MD University of Texas MD Anderson Cancer Center \u2013 Houston, TX, USA<\/em><\/em><\/em><\/div><\/p><\/div><\/li>\n
\na. Colorectal liver metastasis
\nb. Neuroendocrine liver metastasis
\nc. Tumors in the pediatric population and other rare tumor
\nGroup Leaders: Mohamed Rela, MD, Dr.Rela Institute & Medical Centre \u2013 Chennai, India<\/em>
\nTaizo Hibi, MD, PhD, FACS Kumamoto University Graduate School of Medical Sciences Kumamoto, Japan<\/em>
\nJames Eason, MD Methodist University Transplant \u2013 Memphis, TN, USA
\n<\/em><\/em><\/div><\/p><\/div><\/li>\n
\na. Tailored immunosuppression for cancer recipients
\nb. Cancer recurrence prediction models and surveillance strategies
\nc. New adjuvant therapies for recurrence after OLT (chemotherapy, immunotherapy, new biological treatment and radiotherapy)
\nGroup Leaders:Marina Berenguer, MD Hospital La Fe \u2013 Valencia, Spain<\/em>
\nPatrizia Burra, MD, PhD Padova University Hospital \u2013 Padova, Italy<\/em>
\nHerold Metselaar, MD, PhD Erasmus MC \u2013 Rotterdam, The Netherlands<\/em><\/li>\n<\/div><\/p><\/div><\/li>\n<\/ol>\n
\n<\/strong><\/p>\n
\n<\/strong><\/p>\n<\/div><\/p><\/div>\n
\n<\/div><\/p><\/div>\n
\n![\"\"](\"https:\/\/wp-ilts-media.s3.amazonaws.com\/wp-content\/uploads\/2018\/09\/14103310\/index-300x55.jpg\")
<\/p>\n<\/div><\/p><\/div>\n![\"\"](\"https:\/\/wp-ilts-media.s3.amazonaws.com\/wp-content\/uploads\/2018\/09\/14103448\/image_manager__rex_mediapool_maximized_ethical_medtech_logo.png\"){kind=logo}
<\/p>\n<\/div><\/p><\/div>\n<\/div><\/p><\/div>\n<\/div><\/p><\/div>\n
\n
\nVia Matteo Bandello, 1 \u2013 20123 Milano
\nP.I. 02818040152 \u2013 IATA 38220346
\nTel. +39 02.4818691
\nwww.ariadiviaggi.it\u00a0\u00a0\u00a0 <\/a>
\nbarbara.mantegazza@ariadiviaggi.it<\/a><\/p>\n
![\"\"](\"https:\/\/wp-ilts-media.s3.amazonaws.com\/wp-content\/uploads\/2018\/09\/31115704\/novartis_logo_pos_cmyk_u-300x70.png\"){kind=logo}
<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"